Search results
Results from the WOW.Com Content Network
Idiopathic intracranial hypertension (IIH), previously known as pseudotumor cerebri and benign intracranial hypertension, is a condition characterized by increased intracranial pressure (pressure around the brain) without a detectable cause. [2] The main symptoms are headache, vision problems, ringing in the ears, and shoulder pain.
Drug-induced intracranial hypertension (DIIH) or medication-induced intracranial hypertension is a condition of higher than normal intracranial pressure with the main cause being a drug. [15] This condition is similar to idiopathic intracranial hypertension , however the etiology in this instance is a drug. [ 16 ]
Idiopathic intracranial hypertension, or unexplained high pressure in the cranium, is a rare condition that can cause visual impairment, frequent severe headache, and tinnitus. It is most commonly seen in obese women, and the incidence of idiopathic intracranial hypertension is increasing along with increases in the number of people who are obese.
Essential hypertension (also called primary hypertension, or idiopathic hypertension) is a form of hypertension without an identifiable physiologic cause. [1] [2] It is the most common type affecting 85% of those with high blood pressure. [3] [4] The remaining 15% is accounted for by various causes of secondary hypertension. [3]
The utility of the method was successfully confirmed on four healthy subjects and four patients with intracranial hypertension, but larger validation studies have never been conducted as the method failed to attract enough interest among clinicians. This method also needs a calibration to the individual patients.
Former national security adviser H.R. McMaster argued that the ongoing conflict in Gaza will continue and life for Palestinians cannot improve “until Hamas is destroyed.”
Gross merchandise volume growth for the first nine months of the year was 34%, higher than last year but below 2022 levels. Affirm provides credit to consumers at APRs between 0% and 36% ...
Target ranges for hormone levels in hormone therapy for transgender women; Source Place Estradiol, total Testosterone, total Refs Endocrine Society: United States: 100–200 pg/mL